PedAM
Pediatric Disease Annotations & Medicines
| Disease | leukemia |
| Phenotype | C0023473|chronic myeloid leukemia |
| Sentences | 9 |
| PubMedID- 26256879 | [development of ph negative acute myeloid leukemia in a patient with minor-bcr/abl positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment]. |
| PubMedID- 22543830 | Philadelphia-negative acute promyelocytic leukemia in a patient with chronic myeloid leukemia in complete cytogenetic response after treatment with tyrosine kinase inhibitor. |
| PubMedID- 25543705 | [chronic lymphocytic leukemia with concomitant chronic myeloid leukemia: a case report]. |
| PubMedID- 21393960 | Exfoliative dermatitis with leukemia cutis in a patient with chronic myeloid leukemia: a rare association. |
| PubMedID- 24944694 | Promoter hypermethylation has also been found to reduce rtvp-1 expression in acute myeloid leukemia patients compared with lymphoblastic leukemia, chronic myeloid leukemia and remission bone marrow (11). |
| PubMedID- 20377918 | Introduction: the development of philadelphia chromosome (ph) negative acute leukemia/myelodysplastic syndrome (mds) in patients with ph-positive chronic myeloid leukemia (cml) is very rare. |
| PubMedID- 20922786 | Tyrosine kinase inhibitor (tki) treatment targeting breakpoint cluster region-abelson murine leukemia virus, the cause of chronic myeloid leukemia (cml), has revolutionized therapy for patients with this disease. |
| PubMedID- 22184394 | Hairy cell leukemia variant in a patient with chronic myeloid leukemia receiving nilotinib: sequential or coincidental. |
| PubMedID- 23192016 | Using a collection of 55 leukemia patients treated with tki therapy (chronic myeloid leukemia, n=47; acute lymphoblastic leukemia, n=8), we found that dasatinib, a second-generation broad-spectrum tki, induced a rapid, dose-dependent and substantial mobilization of non-leukemic lymphocytes and monocytes in blood peaking 1-2 h after an oral intake and the blood counts closely mirrored drug plasma concentration. |
Page: 1